Insider Transactions Reported by 17 Insiders of Eiger BioPharmaceuticals, Inc.

Location: Palo Alto, CA

Quick Takeaways

Eiger BioPharmaceuticals, Inc. has 17 insiders with reported activity on this page.
No net insider buy/sell flow is currently reported for the last year.
Recent transaction rows are not currently available.

What Changed

No meaningful buy/sell imbalance is currently visible in the one-year window.
Activity will update as new Forms 3/4/5 are filed.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 08 Apr 2025.

Buys

Shares: 0

Insiders: 0

Sells

Shares: 0

Insiders: 0

Net

Shares: 0

Insiders: 0

Window (months)	Buy $	Sell $	Net $
0-3	$0	$0	$0
3-6	$0	$0	$0
6-9	$0	$0	$0
9-12	$0	$0	$0

Eiger BioPharmaceuticals, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Valuation	Report Date
Richard A. Kayne	10%+ Owner	$1,600,204	Filing P/S	31 Oct 2023
Leen Kawas	10%+ Owner	$1,307,329	Mixed	31 Oct 2023
David A. Cory	President and CEO, Director	$50,366	Mixed	11 Mar 2022
Eldon C. Mayer III	Ex VP & Chief Commerc. Officer	$16,693	Mixed	17 Mar 2023
Sriram Ryali	Chief Financial Officer	$12,374	Mixed	14 Mar 2022
Ingrid Choong	Chief Business Officer	$9,972	Mixed	31 Aug 2023
William G. Kachioff	Cfo		Mixed	12 Apr 2023
Thomas John Dietz	Director		Mixed	01 Mar 2023
Evan Loh	Director		Mixed	01 Mar 2023
Erik Atkisson	GC & Chief Compliance Officer		Mixed	26 Jan 2023
David Apelian	CEO, Director		Mixed	03 Jul 2023
Jeffrey S. Glenn	Director		Mixed	01 Mar 2023
Kim Sablich	Director		Mixed	01 Mar 2023
Lisa Kelly-Croswell	Director		Mixed	01 Mar 2023
James Vollins	General Counsel		Mixed	30 Apr 2023
Christine Murray	Director		Mixed	01 Mar 2023
Amit Sachdev	Director		Mixed	01 Mar 2023

Top shareholders of Eiger BioPharmaceuticals, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Richard A. Kayne	3/4/5	10%+ Owner	— class O/S missing	5,375,225	$1,600,204	—	31 Oct 2023	3/4/5
Leen Kawas	3/4/5	10%+ Owner	— class O/S missing	4,391,432	$1,307,329	—	31 Oct 2023	3/4/5
David A. Cory	3/4/5	President and CEO, Director	— mixed-class rows	450,183 mixed-class rows	$50,366	—	11 Mar 2022	3/4/5
Eldon C. Mayer III	3/4/5	Ex VP & Chief Commerc. Officer	— mixed-class rows	154,073 mixed-class rows	$16,693	—	17 Mar 2023	3/4/5
Sriram Ryali	3/4/5	Chief Financial Officer	— mixed-class rows	184,566 mixed-class rows	$12,374	—	14 Mar 2022	3/4/5
Ingrid Choong	3/4/5	Chief Business Officer	— mixed-class rows	87,500 mixed-class rows	$9,972	—	31 Aug 2023	3/4/5
David Apelian	3/4/5	CEO, Director	— class O/S missing	750,000	—	—	03 Jul 2023	3/4/5
James Vollins	3/4/5	General Counsel	— class O/S missing	120,000	—	—	30 Apr 2023	3/4/5
Thomas John Dietz	3/4/5	Director	— class O/S missing	40,000	—	—	01 Mar 2023	3/4/5
Amit Sachdev	3/4/5	Director	— class O/S missing	28,000	—	—	01 Mar 2023	3/4/5
Christine Murray	3/4/5	Director	— class O/S missing	28,000	—	—	01 Mar 2023	3/4/5
Evan Loh	3/4/5	Director	— class O/S missing	28,000	—	—	01 Mar 2023	3/4/5
Jeffrey S. Glenn	3/4/5	Director	— class O/S missing	28,000	—	—	01 Mar 2023	3/4/5
Kim Sablich	3/4/5	Director	— class O/S missing	28,000	—	—	01 Mar 2023	3/4/5
Lisa Kelly-Croswell	3/4/5	Director	— class O/S missing	28,000	—	—	01 Mar 2023	3/4/5
Erik Atkisson	3/4/5	GC & Chief Compliance Officer	— class O/S missing	26,750	—	—	26 Jan 2023	3/4/5

Recent Insider Transactions by Companies or Individuals for Eiger BioPharmaceuticals, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
No insider transactions were found in the last 12 months for this issuer.

* An asterisk sign (*) next to the price indicates that the price is likely invalid.